Publication

B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome

Verstappen, G. M., Kroese, F. G. M., Meiners, P. M., Corneth, O. B., Huitema, M. G., Haacke, E. A., van der Vegt, B., Arends, S., Vissink, A., Bootsma, H. & Abdulahad, W. H., Jan-2017, In : The Journal of Rheumatology. 44, 1, p. 49-58 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome

    Final publisher's version, 4 MB, PDF document

    Request copy

DOI

Objective. To assess the effect of B cell depletion therapy on effector CD4+ T cell homeostasis and its relation to objective measures of disease activity in patients with primary Sjogren syndrome (pSS).

Methods. Twenty-four patients with pSS treated with rituximab (RTX) and 24 healthy controls (HC) were included. Frequencies of circulating effector CD4+ T cell subsets were examined by flow cytometry at baseline and 16, 24, 36, and 48 weeks after the first RTX infusion. Th1, Th2, follicular Th (TFH), and Th17 cells were discerned based on surface marker expression patterns. Additionally, intracellular cytokine staining was performed for interferon-gamma, interleukin (IL)-4, IL-21, and IL-17 and serum levels of these cytokines were analyzed.

Results. In patients with pSS, frequencies of circulating TFH cells and Th17 cells were increased at baseline compared with HC, whereas frequencies of Th1 and Th2 cells were unchanged. B cell depletion therapy resulted in a pronounced decrease in circulating TFH cells, whereas Th17 cells were only slightly lowered. Frequencies of IL-21-producing and IL-17-producing CD4+ T cells and serum levels of IL-21 and IL-17 were also reduced. Importantly, the decrease in circulating TFH cells was associated with lower systemic disease activity over time, as measured by the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index scores and serum IgG levels.

Conclusion. B cell depletion therapy in patients with pSS results in normalization of the elevated levels of circulating TFH cells. This reduction is associated with improved objective clinical disease activity measures. Our observations illustrate the pivotal role of the crosstalk between B cells and TFH cells in the pathogenesis of pSS.

Original languageEnglish
Pages (from-to)49-58
Number of pages10
JournalThe Journal of Rheumatology
Volume44
Issue number1
Publication statusPublished - Jan-2017

    Keywords

  • SJOGREN SYNDROME, RITUXIMAB, B LYMPHOCYTES, T LYMPHOCYTES, AUTOIMMUNITY, SALIVARY-GLANDS, RITUXIMAB TREATMENT, HELPER-CELLS, CYTOKINE PRODUCTION, CONTROLLED-TRIAL, DOUBLE-BLIND, DIFFERENTIATION, EXPRESSION, DISEASE

ID: 38620684